NO20024076L - Sammensetning omfattende camptotecin og et pyrimidinderivat for behandling av cancer - Google Patents

Sammensetning omfattende camptotecin og et pyrimidinderivat for behandling av cancer

Info

Publication number
NO20024076L
NO20024076L NO20024076A NO20024076A NO20024076L NO 20024076 L NO20024076 L NO 20024076L NO 20024076 A NO20024076 A NO 20024076A NO 20024076 A NO20024076 A NO 20024076A NO 20024076 L NO20024076 L NO 20024076L
Authority
NO
Norway
Prior art keywords
cancer
treatment
camptotecin
pyrimidine derivative
composition
Prior art date
Application number
NO20024076A
Other languages
English (en)
Other versions
NO324772B1 (no
NO20024076D0 (no
Inventor
Marie-Christine Bissery
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of NO20024076L publication Critical patent/NO20024076L/no
Publication of NO20024076D0 publication Critical patent/NO20024076D0/no
Publication of NO324772B1 publication Critical patent/NO324772B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20024076A 2000-02-28 2002-08-27 Farmasoytisk kombinasjon omfattende CPT-11 og capecitabin samt anvendelse av nevnte kombinasjon for fremstilling av et preparat for behandling av coloncancer NO324772B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18537800P 2000-02-28 2000-02-28
US20893800P 2000-06-05 2000-06-05
PCT/EP2001/002723 WO2001062235A2 (en) 2000-02-28 2001-02-26 A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer

Publications (3)

Publication Number Publication Date
NO20024076L true NO20024076L (no) 2002-08-27
NO20024076D0 NO20024076D0 (no) 2002-08-27
NO324772B1 NO324772B1 (no) 2007-12-10

Family

ID=26881090

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20024076A NO324772B1 (no) 2000-02-28 2002-08-27 Farmasoytisk kombinasjon omfattende CPT-11 og capecitabin samt anvendelse av nevnte kombinasjon for fremstilling av et preparat for behandling av coloncancer

Country Status (28)

Country Link
US (3) US6503889B2 (no)
EP (1) EP1278518B1 (no)
JP (1) JP2003523980A (no)
KR (1) KR100717916B1 (no)
CN (1) CN1424912A (no)
AT (1) ATE344670T1 (no)
AU (1) AU785467B2 (no)
BR (1) BR0108728A (no)
CA (1) CA2401191C (no)
CY (1) CY1105803T1 (no)
CZ (1) CZ298259B6 (no)
DE (1) DE60124387T2 (no)
DK (1) DK1278518T3 (no)
EA (1) EA005619B1 (no)
EE (1) EE200200471A (no)
ES (1) ES2273841T3 (no)
HR (1) HRP20020658A2 (no)
HU (1) HUP0300848A3 (no)
IL (1) IL150953A0 (no)
MX (1) MXPA02008355A (no)
NO (1) NO324772B1 (no)
NZ (1) NZ520593A (no)
PL (1) PL363110A1 (no)
PT (1) PT1278518E (no)
SK (1) SK12242002A3 (no)
TW (1) TWI239841B (no)
WO (1) WO2001062235A2 (no)
YU (1) YU64602A (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9808052D0 (en) 1998-04-17 1998-06-17 Secr Defence Implants for administering substances and methods of producing implants
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
US20030092608A1 (en) * 2001-08-21 2003-05-15 Takayuki Kawaguchi Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor
US7026301B2 (en) * 2002-10-17 2006-04-11 New York University Method of orally treating inflammatory skin conditions with prodrugs of 5-fluorouracil
ITMI20030317A1 (it) * 2003-02-21 2004-08-22 Pharmacia Italia Spa Terapia combinata comprendente un derivato dell'indolopirrolocarbazolo ed un altro agente antitumorale.
US20050153885A1 (en) * 2003-10-08 2005-07-14 Yun Anthony J. Treatment of conditions through modulation of the autonomic nervous system
ATE406897T1 (de) * 2003-11-13 2008-09-15 Pharma Mar Sau Kombination von et-743 mit 5-fluorouracil pro- drugs zur behandlung von krebs
CA2563502A1 (en) 2004-04-09 2005-10-20 Chugai Seiyaku Kabushiki Kaisha Novel water-soluble prodrug
EP1771174A1 (en) * 2004-05-28 2007-04-11 Pfizer Products Inc. Method for treating abnormal cell growth
CA2569277A1 (en) * 2004-06-04 2005-12-15 Pfizer Products Inc. Method for treating abnormal cell growth
BRPI0511765A (pt) * 2004-06-04 2008-01-08 Smithkline Beechman Cork Ltd métodos de tratar cáncer de mama, de pulmão, e colo-retal em um mamìfero
US8569277B2 (en) 2004-08-11 2013-10-29 Palo Alto Investors Methods of treating a subject for a condition
DE112006000873T5 (de) * 2005-04-12 2008-03-06 Elan Pharma International Ltd. Zusammensetzungen mit modifizierter Freisetzung, umfassend ein Fluorcytidin-Derivate zur Behandlung von Krebs
EP1890537B1 (en) * 2005-06-07 2012-08-08 Yale University Methods of treating cancer and other conditions or disease states using lfmau and ldt
TW200744603A (en) 2005-08-22 2007-12-16 Chugai Pharmaceutical Co Ltd Novel anticancer concomitant drug
CA2758607C (en) 2009-05-04 2018-05-15 Psivida Us, Inc. Porous silicon drug-eluting particles
EP3117709B1 (en) * 2010-03-12 2018-08-01 Genzyme Corporation Combination therapy for treating breast cancer
US9333173B2 (en) 2010-11-01 2016-05-10 Psivida Us, Inc. Bioerodible silicon-based devices for delivery of therapeutic agents
CA2904077A1 (en) 2013-03-15 2014-09-25 Psivida Us, Inc. Bioerodible silicon-based compositions for delivery of therapeutic agents

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57116015A (en) 1981-01-09 1982-07-19 Yakult Honsha Co Ltd Antitumor agent
US4399276A (en) 1981-01-09 1983-08-16 Kabushiki Kaisha Yakult Honsha 7-Substituted camptothecin derivatives
JPS57116074A (en) 1981-01-09 1982-07-19 Yakult Honsha Co Ltd Novel camptothecin derivative and its preparation
US4473692A (en) 1981-09-04 1984-09-25 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives and process for preparing same
JPS58154582A (ja) 1982-03-10 1983-09-14 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体およびその製造法
JPS595188A (ja) 1982-06-30 1984-01-12 Yakult Honsha Co Ltd １０−ヒドロキシカンプトテシンの製造法
JPS5951289A (ja) 1982-09-17 1984-03-24 Yakult Honsha Co Ltd 新規な９−置換−カンプトテシン誘導体
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
US4981968A (en) 1987-03-31 1991-01-01 Research Triangle Institute Synthesis of camptothecin and analogs thereof
CA1332413C (en) 1987-06-25 1994-10-11 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives and process for preparing same
US5004758A (en) 1987-12-01 1991-04-02 Smithkline Beecham Corporation Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells
JPH0615547B2 (ja) 1988-01-20 1994-03-02 株式会社ヤクルト本社 新規なカンプトテシン誘導体
JP2524804B2 (ja) 1988-03-29 1996-08-14 株式会社ヤクルト本社 新規なカンプトテシン誘導体及びその製造法
JP2524803B2 (ja) 1988-03-29 1996-08-14 株式会社ヤクルト本社 新規なカンプトテシン誘導体およびその製造法
US5552154A (en) * 1989-11-06 1996-09-03 The Stehlin Foundation For Cancer Research Method for treating cancer with water-insoluble s-camptothecin of the closed lactone ring form and derivatives thereof
EP0540099B1 (en) 1991-10-29 1996-04-17 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
AU671491B2 (en) * 1992-12-18 1996-08-29 F. Hoffmann-La Roche Ag N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
US6504029B1 (en) 1995-04-10 2003-01-07 Daiichi Pharmaceutical Co., Ltd. Condensed-hexacyclic compounds and a process therefor
GB9510716D0 (en) 1995-05-26 1995-07-19 Pharmacia Spa Substituted camptothecin derivatives and process for their preparation
US5670500A (en) 1995-05-31 1997-09-23 Smithkline Beecham Corporation Water soluble camptothecin analogs
US5663177A (en) 1995-05-31 1997-09-02 Smithkline Beecham Corporation Water soluble camptothecin analogs
DK1251125T3 (da) 1995-06-21 2006-04-18 Sod Conseils Rech Applic Hidtil ukendte camptothecin-analoger, fremgangsmåde til fremstilling heraf, anvendelse heraf som lægemidler og farmaceutiske præparater indeholdende disse
MXPA01006742A (es) * 1998-12-31 2004-04-21 Sugen Inc Compuestos 3-heteroarilidenil-2-indolinona para modular la actividad de la quinasa de proteina y para utilizarse en la quimioterapia de cancer.
US6191119B1 (en) 1999-10-15 2001-02-20 Supergen, Inc. Combination therapy including 9-nitro-20(S)-camptothecin
GB9925127D0 (en) * 1999-10-22 1999-12-22 Pharmacia & Upjohn Spa Oral formulations for anti-tumor compounds

Also Published As

Publication number Publication date
AU6011101A (en) 2001-09-03
TWI239841B (en) 2005-09-21
EA200200922A1 (ru) 2003-04-24
NZ520593A (en) 2004-10-29
KR100717916B1 (ko) 2007-05-11
HRP20020658A2 (en) 2004-12-31
US20020091132A1 (en) 2002-07-11
WO2001062235A3 (en) 2002-11-14
EA005619B1 (ru) 2005-04-28
YU64602A (sh) 2005-06-10
CN1424912A (zh) 2003-06-18
US20020068743A1 (en) 2002-06-06
CY1105803T1 (el) 2011-02-02
EP1278518B1 (en) 2006-11-08
HUP0300848A2 (hu) 2003-08-28
EP1278518A2 (en) 2003-01-29
WO2001062235A2 (en) 2001-08-30
PL363110A1 (en) 2004-11-15
KR20020082856A (ko) 2002-10-31
CA2401191A1 (en) 2001-08-30
DE60124387D1 (de) 2006-12-21
DK1278518T3 (da) 2007-01-15
US20030096789A1 (en) 2003-05-22
DE60124387T2 (de) 2007-10-11
NO324772B1 (no) 2007-12-10
ES2273841T3 (es) 2007-05-16
US6664242B2 (en) 2003-12-16
PT1278518E (pt) 2007-01-31
AU785467B2 (en) 2007-07-26
EE200200471A (et) 2003-12-15
CZ20022892A3 (cs) 2002-11-13
NO20024076D0 (no) 2002-08-27
SK12242002A3 (sk) 2003-02-04
IL150953A0 (en) 2003-02-12
CA2401191C (en) 2006-05-02
JP2003523980A (ja) 2003-08-12
ATE344670T1 (de) 2006-11-15
MXPA02008355A (es) 2002-12-13
US6503889B2 (en) 2003-01-07
HUP0300848A3 (en) 2005-03-29
BR0108728A (pt) 2003-12-30
CZ298259B6 (cs) 2007-08-08

Similar Documents

Publication Publication Date Title
NO20024076D0 (no) Sammensetning omfattende camptotecin og et pyrimidinderivat for behandling av cancer
NO20050807L (no) Farmasoytiske sammensetninger som innbefatter dekstrometorfan og kinidin for behandling av neurologiske forstyrrelser
NO20024610D0 (no) Synergistiske metoder og blandinger for behandling av kreft
CY1105225T1 (el) Παραγωγα 5-β-σαπωγενινης και ψευδοσαπωγενινης και η χρηση τους στην αντιμετωπιση ανοιας
DE602004017194D1 (de) Pyridylpyrrol-derivate als wirksame kinase-hemmer
TR200100054T2 (tr) Paroksetin metansülfonat
DK1259240T3 (da) Midler, såsom nikotinamid eller CADPR, til behandling af hudsygdomme
PT1017675E (pt) Derivados da camtotecina altamente lipofilos
AR034343A1 (es) Combinaciones farmaceuticas
EP1503748A4 (en) DRUGS TO REDUCE TAXAN-INDUCED NEUROTOXICITY
DK1383516T3 (da) Indgivelse af et polysaccharid samtidig med et kemoterapeutisk middel til behandling af cancer
BR0113165A (pt) Derivados de 4-pirimidinamina, composições farmacêuticas e métodos relacionados
NO20031410D0 (no) Antitumorterapi innbefattende distamycinderivater
MXPA04001912A (es) Aminobenzofenonas novedosas.
TR200302134T4 (tr) 2-metil-tiazolidin-2,4-dikarboksilik asit ve/veya bunun fizyolojik olarak uygun tuzlarının anti-kanser ajanları olarak kullanımı.
WO2002078690A3 (en) Taxoid anti-tumor agents and pharmaceutical compositions thereof
RS60604A (en) Carboxamidine derivatives and their use in the treatment of vascular diseases
HUP0302629A2 (hu) Camptotechin és sztilbénszármazékok kombinációját tartalmazó gyógyszerkészítmények rák kezelésére
NO20006547L (no) Salter av paroxetine
NO20055888L (no) Kombinasjonsterapi
EA200500175A1 (ru) Соль морфин-6-глюкуронида
NO20075508L (no) Stannsoporfinpreparater og administrering
EP1221945A4 (en) METHOD AND PHARMACEUTICAL AND THERAPEUTIC COMPOSITIONS FOR THE ADMINISTRATION OF ADENOSINE
ATE371446T1 (de) Zusammensetzungen zur verhinderung der adhäsion
BR0107726A (pt) Composto, composição farmacêutica, e, métodos de tratamento de um paciente canceroso, de inibição de proteìna quinases em um paciente, de inibição de quinases dependentes de ciclina em um paciente, e de preparação do composto